

CURRICULUM VITAE

MICHAEL I. BUKRINSKY, M.D., Ph.D., FAHA

Professor of Microbiology, Immunology and Tropical Medicine

Professor of Biochemistry and Molecular Medicine

CITIZENSHIP USA

ADDRESS: Department of Microbiology & Tropical Medicine
The George Washington University
Ross Hall Rm. 624
2300 I St., N.W.
Washington, DC 20037
Tel. (202) 994-2036; FAX (202) 994-2913;
E-mail: mbukrins@gwu.edu

EDUCATION:

1972 -1978 2nd Moscow Medical Institute, Moscow, USSR
Graduate student in Biochemistry
M.D. granted July, 1978

1980-1984 Laboratory of Nucleic Acids Biosynthesis
Institute of Molecular Biology, USSR Academy of Sciences
Ph.D. granted in December, 1984
Ph.D. thesis: DNA sequences of the mouse genome homologous to long double-stranded RNA: Structure and transcription.

PROFESSIONAL EXPERIENCE:

Sept. 1978- Laboratory of Molecular Microbiology, Institute of Microbiology and
Nov. 1980 Epidemiology, USSR Academy of Medical Sciences.
Research Assistant

Jan. 1984- Laboratory of Virus Physiology, D. I. Ivanovski Institute of Virology, USSR
April 1986 Academy of Medical Sciences.
Postdoctoral Research Associate

May 1989- Laboratory of Virus Physiology, D. I. Ivanovski Institute of Virology, USSR
April 1986 Academy of Medical Sciences.
Assistant Professor

Feb. 1990- Department of Pathology and Microbiology, University of Nebraska
June 1991 Medical Center.
Postdoctoral Research Associate

July 1991- Department of Pathology and Microbiology, University of Nebraska
July 1992 Medical Center.
Instructor

July 1992- Department of Pathology and Microbiology, University of Nebraska
Oct. 1992 Medical Center.
Assistant Professor

Nov. 1992- The Picower Institute for Medical Research
Aug. 1997 Associate Professor

Aug. 1997- The Picower Institute for Medical Research
Sep. 2001 Professor

Sep. 2001- The George Washington University School of Medicine and Health Sciences
present Professor, Department of Microbiology, Immunology & Tropical Medicine

Sep. 2005- The George Washington University School of Medicine and Health Sciences
present Professor of Biochemistry and Molecular Medicine

July 2011 - Interim Chair, Department of Microbiology, Immunology and Tropical
Oct 2013 Medicine, George Washington University School of Medicine and Health
Sciences

July 2018 – Interim Chair, Department of Microbiology, Immunology and Tropical
July 2019 Medicine, George Washington University School of Medicine and Health
Sciences

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

1993-Present American Society for Microbiology
2005-Present American Heart Association
1994-2008 American Association for the Advancement of Science
1995-Present New York Academy of Sciences
1997-2010 American Society for Biochemistry and Molecular Biology
2001-Present International AIDS Society

AWARDS:

1983 Institute of Molecular Biology Award for Young Scientists
1985 Institute of Virology Award for Young Scientists
1987 USSR State Award for Young Scientists
2007 GWU Distinguished Scientist Award
2011 Oscar and Shoshana Trachtenberg Prize for GW Scholarship
2011 Fellow of the American Heart Association

FUNDING (total direct costs):

1988 - 1989 Principal Investigator, USSR Academy of Medical Sciences. "Analysis of HIV-1 gene expression," #10-15/126; \$9,000.
1992 - 1993 Principal Investigator, Nebraska Cancer & Smoking Disease Research Program, "Early Steps in HTLV-1 Infection: New Targets for Therapy," #LB506-93-08; \$80,000.
1992 - 1994 Principal Investigator, AmFAR, "HIV-1 Replication in Mononuclear Phagocytes *in vivo*," #001829-13-RGT; \$120,000.
1996 - 1999 Principal Investigator, NIH, NIAID, "Mechanisms of HIV-induced dysregulation of monocytes," R01 AI 38245; \$700,000.

- 1993 - 2007 Principal Investigator, NIH, NIAID, "Role of Vpr in HIV-1 Nuclear Translocation," R01 AI 33776, \$1,250,000.
- 2001 - 2005 Principal Investigator, NIH, NIAID, "Nuclear translocation of HIV-1 genome as a drug target," R01 AI 46586, \$1,250,000.
- 2002 - 2004 Principal Investigator, NIH, NIAID, "Imaging Technology for HIV Nuclear Import Inhibitors," R21 AI 53806, \$300,000.
- 2003 - 2005 Principal Investigator, NIH, NIAID, "HIV Infection and Reverse Cholesterol Transport," R03 TW 06238, \$100,000.
- 2003 - 2005 Principal Investigator, NIH, NIAID, "CD4+ Memory T Cell Recruitment by Cyclophilin", R03 AI 057018, \$100,000.
- 2004 - 2006 Principal Investigator, NIH, NIAID, "Leukocyte recruitment by cyclophilin-CD147 interaction," R21 AI 060720, \$300,000
- 2005 - 2007 Principal Investigator, AHA, "Impairment of reverse cholesterol transport by HIV: a possible mechanism of atherosclerosis in HIV patients", 05554222U, \$120,000.
- 2005 - 2007 Principal Investigator, NIH, NIDDK, "HIV impairs reverse cholesterol transport", R21 DK072926, \$275,000.
- 2007-2009 Principal Investigator, NIH, NIAID, "Oxadaizols: Rationally designed compounds targeting HIV nuclear importation", R21 AI071837, \$275,000
- 2007-2009 Principal Investigator, AHA, "Cholesterol efflux and HIV infectivity: potent anti-viral effect of ABCA1-stimulating compounds", 0755357U, \$120,000.
- 2006-2011 Co-Investigator, NIH, NIAID, "Contribution of cyclophilins to leukocyte recruitment in lung inflammation", R01 AI067254, \$1,250,000 (PI: S. Constant).
- 2009-2011 Principal Investigator, NIH, NIAID, "Targeting HIV infectivity by stimulating cholesterol efflux", R21 AI078743, \$275,000.
- 2009-2014 Principal Investigator, NIH, NIHLB, "Mechanisms of virus-induced impairment of reverse cholesterol transport", R01 HL093818, \$1,250,000.
- 2009-2011 Principal Investigator, NIH, NIAID, "Cyclophilin-CD147 interaction in autoimmune arthritis", R56 AI081152, \$500,000.
- 2009-2011 Principal Investigator, CRDF, "Design of chimerical expression cassettes producing biologically active siRNAs targeting both the conserved regions in HIV-1 transcripts and regions in CCR5 mRNA", RUB2-2960-MO-09, \$80,000.

- 2009-2012 Principal Investigator, Department of Education, “Training leaders for 21st century biotechnology: Joint GWU-MSU Educational Program”, P116S090023, \$450,000.
- 2010-2015 Principal Investigator, NIH, NIHLB, “HIV Disease and Impairment of High Density Lipoprotein Metabolism”, R01 HL101274, \$2,500,000.
- 2010-2015 Developmental and Basic Science Core Director, NIH Program Project “The District of Columbia Developmental Center for AIDS Research”, P30 AI055019, \$3,750,000 (PI: A. Greenberg).
- 2014-2016 Principal Investigator, NIH, NIAID, “HIV-1 Nef regulates activity of the ER chaperone calnexin”, R21 AI108533, \$275,000.
- 2015-2017 Principal Investigator, NIH, NIAID, “Structural characterization of the Nef-calnexin complex”, R21 AI114471, \$275,000.
- 2016-2020 Principal Investigator, NIH, NHLBI, “Metabolic complications of HIV disease caused by Nef released from HIV-infected cells”, R01 HL131473, \$1,200,000.
- 2017-2019 Principal Investigator, AHA, “Epigenetic reprogramming in HIV-associated atherosclerosis”, 17GRNT33630163, \$154,000.
- 2017-2020 Principal Investigator, NIH, NINDS, “Nef and neuroAIDS: role of cholesterol metabolism impairment and inflammation”, R01 NS102163, \$450,000.
- 2018-2020 PD/PI (contact PI – Dr. G. Enikolopov), NIH, NIMH, “Alterations in neuronal networks induced by cART and HIV”, R21 MH118991, \$275,000.
- 2018-2022 Principal Investigator, NIH, NHLBI, “Epigenetic reprogramming in HIV-associated cardio-vascular disease”, R01 HL140977, \$2,000,000.
- 2015-2025 Director of Developmental Core (PI – Dr. Alan Greenberg). NIH, NIAID, “DC CFAR”, P30 AI117970, \$7,500,000.
- 2021-2025 Principal Investigator, NIH, NHLBI, “Lipid raft therapy – a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities”, R01 HL158305, \$2,000,000.
- 2021-2026 Principal Investigator, NIH, NINDS, “Novel pathogenic mechanism of HIV-associated CNS neurological disorders”, R01 NS124477, \$2,500,000.
- 2022-2024 Principal Investigator, NIH, NIAID, “Trained immunity induced by Nef-containing extracellular vesicles”, R21 AI172028, \$275,000.

2022-2024 PD/PI (contact PI – Dr. A. Kulkarni), NIH, NINDS, “Development of NLRP3 inhibitors for HIV-associated neuroinflammation”, R21 NS129478, \$275,000.

ACADEMIC EXPERIENCE:

Organizer of the courses in molecular biology of HIV and molecular virology for graduate students and post-doctoral researchers at The Picower Graduate School for Molecular Medicine, 1998-2001

Member of the Admission Committee for the Picower Institute Graduate School for Molecular Medicine (1999-2001)

Member of the GWU Institute for Biomedical Sciences (2002-present)

Adjunct Professor of Immunology and Molecular Biology, Moscow State University, Russia (2006-present)

EDUCATIONAL EXPERIENCE:

Undergraduate Students

Sareena Brown – summer 2005, R03 grant minority supplement

Trina Quabili – summer 2010, R21 grant supplement

Spiridon Vonortas – 2013 – 2014, Luther Rice Undergraduate Research Fellow 2014

Kiera Williams – summer 2015, STEP UP fellowship program

Jaden White – summer 2016, STEP UP fellowship program

Thomas Crow – 2018.

Master of Science Students

Mandeep Gill (GWU) – MS Degree Thesis, 2009-2010

Ruth Hunegnaw (Heidelberg University, Germany) – part of MS Degree Thesis, 2010

Yanjun Feng (GWU) - MS Degree Thesis, 2010-2011; First Prize for students’ presentations (2011)

Yue Zheng (GWU) – MS Degree Thesis, 2014-2015

PhD Students

Mentor

Evgeniy Barsov (1985-1989). Ph.D. degree granted in 1989

Sergey Popov (1985-1989). Ph.D. degree granted in 1989

Zahedi Mujawar (2003-2007). First Prize for oral presentation from ASM on Washington DC Branch Student Day, 2004; Graduate Student Research Award of the Columbian College of Arts and Sciences of GWU, 2006; ASM Raymond W. Sarber Award, 2007. Ph.D. degree granted in 2007

Patrick Morrow (2003-2007). Ph.D. degree granted in 2007

Angela Grant (2007-2010). Ph.D. degree granted in 2010

Lucas Jennelle (2007-2013). First Prize for oral presentation on GW Research Day (2011). Ph.D. degree granted in 2013

Steven Santos (2011-2015). Ph.D. degree granted in 2015

Ruth Hunegnaw (2012-2016). Ph.D. degree granted in 2016

Jessica Schenck (2018 -).

Dissertation Committee Member

Cynthia de la Fuente, 2005; Elena Gustchina, 2005; William M. Gwinn, 2006; Maryam Alrashid, 2007; Javier Guenaga, 2010; Ian Toma, 2011; Andrew Wilson, 2021; Indra Sarabia, 2021.

Rotation Students

Zack Klase, 2004; Shannon Heine, 2005; Mariel Figueroa, 2007; Laura Marxreiter, 2007; Steven Santos, 2011; Ruth Hugenaw, 2011; Andrew Wilson, 2016; Jessica Schenck, 2017; Tony James, 2018; Joshua Ghofrani, 2019.

Medical Students

Alisha Laborico (2003), 2003 National Medical Fellowship from Bristol-Myers Squibb; Anita McElroy (2006).

Post-Doctoral Trainees

Name	Dates in the lab	Current position
------	------------------	------------------

May-Ann Lee	1993-1995	Senior Research Scientist, Singapore Army Institute, Singapore
Helena Schmidtmayerova	1994-2000	Associate Professor, University of Miami, Miami, FL
Vyacheslav Yurchenko	1996-2001	Professor, University of Ostrava, Ostrava, Czech Republic
Sergey Popov	1995-2000	Associate Professor, University of Massachusetts, Worcester, MA
Gabriele Zybarth	1995-1999	Senior Scientist, Pfizer, Mystic, CT
Norbert Reiling	1997-1998	Professor, Research Center Borstel, Division of Microbial Interface Biology, Borstel, Germany
Massimo Alfano	1997-2001	Senior Scientist, DIBIT, Scientific Institute San Raffaele, Milan, Italy
Isabelle Agostini	1998-2001	Scientist, European Cancer Institute, Milan, Italy
Paola DiMarzio	1999-2002	Senior Scientist, NS-LIJ Research Institute
Christophe Vanpouille	2004-2006	Staff Scientist, NIH, NICHD
Sergey Iordanskiy	2000-2007	Assistant Professor, USUHS
Yongsen Wang	2022	current

ADVISORY COMMITTEES

Member of the Scientific Advisory Board of the International Therapeutics Inc., Seattle, WA
– 2002 – 2010

Principal Reviewer for the HIV project on the Site Visit of The Laboratory of Cellular and Molecular Biophysics, NICHD, NIH – 1999, 2003, 2008

Ad Hoc Reviewer for NIH Study Section AMCB – 2001-2011

Ad Hoc Reviewer for NIH Study Section AARR2 – 2003

Ad Hoc Reviewer for Wellcome Trust – 2000, 2004–present

Ad Hoc Reviewer for The Singapore Agency for Science, Technology and Research – 2006

Ad Hoc Reviewer for NHRMC (Australia) – 2005-2006

Ad Hoc Member of the amfAR Scientific Advisory Committee - 2003

Reviewer of the George Mason University Ph.D. Program in Biodefense – 2003

Chairman of the NIH Study Section Meeting ZRG1-AARR-E(05) (S) – 2004

Member of the MARCE Ad Hoc Review Committee – 2005-present

Co-Chair of the AHA Immunology/Virology Review Panel – 2008

Reviewer for the Health Research Board (Ireland) – 2009

Permanent member of the AMCB Study Section – 2011 – 2015

Reviewer for the HIV project on the Site Visit of NICHD, NIH – 2018

Chairman of the NIH Study Section Meeting ZAI1-LK-W (J2) – 2020

Ad hoc reviewer for Czech Science Foundation - 2021

Reviewer for Russian Science Foundation - current

Ad hoc reviewer for NIH Study Sections - current

PEER REVIEW AND EDITORIAL BOARDS:

Ad hoc reviewer for *Nature*, *Nature Medicine*, *Nature Reviews*, *Journal of Experimental Medicine*, *Journal of Virology*, *Journal of Infectious Diseases*, *AIDS Research and Human Retroviruses*, *Journal of Immunology*, *Journal of Immunological Methods*, *Antiviral Research*, *European Journal of Immunology*, *PLoS Pathogens*, *Cell Reports*

Associate Editor, *Frontiers in Bioscience*, 1997 - 1999

Member of the Editorial Board, *Virology*, 2006 – present

Member of the Editorial Board, *Retrovirology*, 2006 – present

Member of the Editorial Board, *The Open Medicine Journal*, 2006 – present

Member of the Editorial Board, *The Open Virology Journal*, 2006 – present

Member of the Editorial Board, *Cholesterol*, 2006 – present

Member of the Editorial Board, *Virology: Research and Treatment*, 2011 - present

Editor, *Advances in Virology*, 2010 - present

Contributing Editor, *Molecular Medicine*, 2006 – present

Member of the Editorial Advisory Board, *Recent patents on Anti-Infective Drug Discovery*, 2006

Editor-in-Chief, *Open AIDS Journal*, 2010 – present

Editor-in-Chief of the HIV vaccines section, *Vaccines*, 2020 – present

PATENTS:

1. **Bukrinsky M.I.**, Barsov E.V., Bukrinskaya A.G., Zhdanov V.M. Recombinant plasmid DNA pUC env2 encoding HTLV-III envelope polypeptide and *Escherichia coli* strain producing env-specific polypeptides. USSR Patent #1,400,072 (1986).
2. **Bukrinsky M.I.**, Popov S.A., Barsov E.V., Bukrinskaya A.G., Zhdanov V.M., Slepushkin V.A. Recombinant plasmid DNA pGS tat 3 encoding HIV antigen and vaccinia virus strain expressing HIV antigen. USSR patent #1,471,563 (1987).
3. **Bukrinsky M.I.**, Cerami A., Ulrich P. Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions. US patents #5,574,040 (1996), #5,620,983 (1997), #5,703,086 (1997), #5,733,932 (1998).
4. **Bukrinsky M.I.**, Cerami A., Ulrich P. Compounds for treating infectious diseases. US patent #5,840,893 (1998).
5. **Bukrinsky M.I.**, Sherry B.A., Ulrich P.C., Cerami A. Treatment of HIV-infection by interfering with host cell cyclophilin receptor activity. US patent #5,840,305 (1998).
6. Pan S., **Bukrinsky M.I.**, Haffar O.K. HIV nuclear localization inhibitors. US patent #5,808,068 (1998).
7. Pan S., **Bukrinsky M.I.**, Haffar O.K. HIV matrix protein tyrosine position 29 pocket binders. US patent #5,849,793 (1998).
8. **Bukrinsky M.I.**, Alfano M. Anti-viral treatment with pertussis toxin B-oligomer. US patent #6,019,979 (2000).
9. Tracey K.J., Cohen P., **Bukrinsky M.I.**, Schmidtmayerova H. Guanyldrazones useful for treating diseases associated with T cell activation. US patent #6,143,728 (2000).
10. **Bukrinsky M.I.**, Sviridov D. Method of suppressing human immunodeficiency virus (HIV) replication in a subject by administering a liver X receptor (LXR) agonist. US patent 8,470,526 (2006).

11. Fischer G., Malesevic M. Erdmann F., Kühling J., **Bukrinsky M.I.**, Constant S. Cyclosporin derivatives. US 8,618,065 (2009).
12. Miller Y., Sviridov D., **Bukrinsky M.** Compositions and methods to treat viral infection and co-morbidities. 0321.139319US (2022).

RESEARCH ARTICLES:

1. Sabelnikov A.G., **Bukrinsky M.I.**, Ilyashenko B.N. (1981). Entry of double and single-stranded linear DNA into Ca^{2+} -treated *E. coli* cells. *Mol. Biol.* (Russian) 15:403-407.
2. **Bukrinsky M.I.**, Sabelnikov A.G. (1981). Quantity of exogenous linear DNA absorbed by *E. coli* cells treated with Ca^{2+} cations. *Bull. Eksp. Biol. Med.* (Russian) 5:594-596.
3. Sabelnikov A.G., **Bukrinsky M.I.**, Ilyashenko B.N. (1983). Structural changes of exogenous DNAs in the process of homologous transformation of *E. coli*. *Mol. Gen. Mikrobiol. Virusol.* (Russian) 4:29-33.
4. **Bukrinsky M.I.**, Kramerov D.A. (1984). Repetitive sequences of the A2 genome family in mice: size and transcription characteristics. *Dokl. Acad. Nauk SSSR* (Russian) 178:231 - 233.
5. **Bukrinsky M.I.**, Kramerov D.A. (1984). Characteristics of the gene transcription of the intracisternal A-particles. *Vopr. Virusol.* (Russian) 3:345-350.
6. Kramerov D.A., **Bukrinsky M.I.**, Ryskov A.P. (1985). DNA sequences homologous to long double-stranded RNA Transcription of intracisternal A-particle genes and major long repeat of the mouse genome. *Biochim. Biophys. Acta* 826:20-29.
7. **Bukrinsky M.I.**, Kovtunencko L.V, Ulyashenko B.N. (1986). Rapid method for analyzing the plasmid DNA of *Bacillus cereus*. *Mol. Gen. Mikrobiol. Virusol.* (Russian) 9:22-24.
8. **Bukrinsky M.I.**, Barsov E.V., Karamov E.V. (1986). Generation of HTLV-III-specific polypeptides in *E. coli* cells. *Vopr. Virusol.* (Russian) 4:489-493.
9. **Bukrinsky M.I.**, Barsov E.V., Zhdanov V.M. (1986). Cloning and expression of HTLV-III env gene fragment in *Escherichia coli* cells. *Dokl. Akad. Nauk SSSR* (Russian) 289:498-499.
10. Slepushkin V.A., **Bukrinsky M.I.** (1987). Effective method of introducing plasmid DNA into eukaryotic cells by using liposomes for producing vaccinia virus recombinants. *Bull. Eksp. Biol. Med.* (Russian) 10:478-480.
11. Tentsov Y.Y., **Bukrinsky M.I.** (1987). Detection of HTLV-III-specific sequences in T-lymphocyte lines by molecular hybridization. *Vopr. Virusol.* (Russian) 2:219-221.
12. Kovtunencko L.V., **Bukrinsky M.I.**, Ilyashenko B.N. (1987). Plasmid transformation of *Bacillus cereus* protoplasts. *Mol. Gen. Mikrobiol. Virusol.* (Russian) 11:27-30.
13. **Bukrinsky M.I.**, Barsov E.V., Karamov E.V. (1988). Use of recombinant proteins carrying antigenic determinants of the envelope proteins of AIDS virus in the diagnosis of acquired immunodeficiency syndrome. *Bull. Eksp. Biol. Med.* (Russian) 5:577-578.

14. **Bukrinsky M.I.**, Zlobin A.Y., Arakelov S.A., Popov S.A., Chaplinskias S.A., Eremin V.F., Korneeva M.N., Nosik D.N., Rudneva I.A., Karamov E.V., Rytik P.G., Stakhanova V.M., Uryvaev L.V. (1988). An analysis of blood sera by the immunoblot method using natural and recombinant antigens of the human immunodeficiency virus. *Vopr. Virusol.* (Russian) 6:700-703.
15. Popov S.A., Barsov E.V., **Bukrinsky M.I.**, Zhdanov V.M. (1988). Expression of gag gene of human immunodeficiency virus in recombinant vaccinia virus. *Mol. Gen. Mikrobiol. Virusol.* (Russian) 9:36-39.
16. **Bukrinsky M.I.**, Barsov E.V., Shilov A.A. (1988). Multicopy expression vector based on temperature-regulated *lac* repressor expression of human immunodeficiency virus *env* gene in *E. coli*. *Gene* 70:415-417.
17. **Bukrinsky M.I.**, Briune I.R., Barteleml L.L. (1989). A study of strains of the human immunodeficiency virus type 1, isolated from 3 patients by a molecular hybridization method. *Vopr. Virusol.* (Russian) 3:342-343.
18. Barsov E.V., **Bukrinsky M.I.** (1989). Construction of a novel vector for thermo-regulated gene expression. Synthesis of a polypeptide carrying HIV antigenic determinants in *E.coli* cells. *Biotechnologia* (Russian) 5:4-8.
19. **Bukrinsky M.I.**, Chaplinskias S.A., Syrtsev V.A., Bravkilene L.A., Philippov Yu.V. (1988). Reactivity to *gag*- and *env*- related proteins in immunoblot assay is not necessarily indicative of HIV infection. *AIDS* 2:405-406.
20. **Bukrinsky M.I.**, Syrtsev V.A., Popov S.A., Barsov E.V., Chaplinskias S.A., Karamov E.V. (1989). False-positive sera do not react with human immunodeficiency virus (HIV) Gag encoded recombinant antigen. *J. Med. Virol.* 27:72-75.
21. Etkin A.F., **Bukrinsky M.I.** (1989). Heterogeneity of the ARV-2 strain and natural isolates of the human immunodeficiency virus. *Arch. Virol.* 108:271-277.
22. **Bukrinsky M.I.**, Etkin A.F. (1990). Plus strand of the HIV provirus DNA is expressed at early stages of infection. *AIDS Res. Human Retroviruses* 6:425-426.
23. **Bukrinsky M.I.**, Vzorov A.N., Bukrinskaya A.G. (1990). Intracellular localization of recombinant vaccinia virus-produced HIV antigens and their use for confirmation of HIV seropositivity. *Acta Virol.* 34:487-492.
24. Vzorov A.N., **Bukrinsky M.I.**, Grygoryev V.B., Tentsov Y.Y., Bukrinskaya A.G. (1991). Highly immunogenic human immunodeficiency virus-like particles are produced by recombinant vaccinia virus infected cells. *AIDS Res. Human Retroviruses* 7:29-36.
25. Haggerty S., Dempsey M.P., **Bukrinsky M.I.**, Guo L., Stevenson M. (1991). Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection. *AIDS Res. Human Retroviruses* 7:429-438.
26. **Bukrinsky M.I.**, Stanwick T.L., Dempsey M.P., Stevenson M. (1991). Quiescent T Lymphocytes as an inducible reservoir in HIV-1 infection. *Science* 254:423-427.

27. **Bukrinsky M.I.**, Sharova N.K., Dempsey M.P., Stanwick M.P., Bukrinskaya A.G., Haggerty S., Stevenson M. (1992). Active nuclear transport of HIV-1 preintegration complexes. *Proc. Natl. Acad. Sci. U.S.A.* 89:6580-6584.
28. **Bukrinsky M.I.**, Sharova N., McDonald T.L., Pushkarskaya T., Tarpley W.G., Stevenson M. (1993). Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. *Proc. Natl. Acad. Sci. U.S.A.* 90:6125-6129.
29. **Bukrinsky M.I.**, Sharova N.K., Stevenson M. (1993). Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. *J. Virol.* 67:6863-6865.
30. **Bukrinsky M.I.**, Haggerty S., Dempsey M.P., Sharova N., Adzhubei A., Spitz L., Lewis P., Goldfarb D., Emerman M., Stevenson M. (1993). A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. *Nature* 365:666-669.
31. Gulizia J., Dempsey M.P., Sharova N., **Bukrinsky M.I.**, Spitz L., Goldfarb D., and Stevenson M. (1994). Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. *J. Virol.* 68:2021-2025.
32. Heinzinger N.*, **Bukrinsky M.I.***, Haggerty S., Ragland A., Kewalramani V., Lee M-A., Gendelman H., Ratner L., Stevenson M., Emerman M. (1994). The HIV-1 Vpr protein is a component of the viral pre-integration complex which influences nuclear targeting of viral, nucleic acids in non-dividing host cells. *Proc. Natl Acad. Sci. U.S.A.* 91:7311 -7315.
- *Equal contribution.
33. Emerman M., **Bukrinsky M.**, and Stevenson M. (1994). HIV-1 infection of non-dividing cells. *Nature* 369:107-108.
34. **Bukrinsky M.**, Nottet H.S.L.M., Schmidtmayerova H., Dubrovsky L., Flanagan C.R., Mullins M.E., Lipton S.A., and Gendelman H.E. (1995). Regulation of nitric oxide synthase activity in HIV-1 monocytes: Implications for HIV-associated neurological diseases. *J. Exp. Med.* 181:735-745.
35. Dubrovsky L., Ulrich P., Nuovo G.L., Manogue K.R., Cerami A., and **Bukrinsky M.** (1995). Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention. *Mol. Med.* 1:217-230.
36. Bianchi M., Ulrich P., Bloom O., Meistrell M., Zimmerman G.A., Schmidtmayerova H., **Bukrinsky M.**, Donnelley T., Bucala R., Sherry B., Manogue K., Tortolani A.J., Cerami A., Tracey K.J. (1995). An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. *Mol. Med.* 1:254-266.
37. **Bukrinsky M.**, Manogue K., and Cerami A. (1995). HIV results in the frame: Other approaches. *Nature* 375:195-196 (Correspondence).

38. Bianchi M., Bloom O., Raabe T., Cohen P.S., Chesney J., Sherry B., Schmidtmayerova H., Zhang X., **Bukrinsky M.**, Ulrich P., Cerami A., and Tracey K. (1996). Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. *J. Exp. Med.* 183:927-936.
39. Schmidtmayerova H., Nottet H.S.L.M., Nuovo G., Raabe T., Flanagan C.R., Dubrovsky L., Gendelman H.E., Cerami A., **Bukrinsky M.**, and Sherry B. (1996). HIV-1 infection alters \square chemokine peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. *Proc. Natl. Acad. Sci. U.S.A.* 93:700-704.
40. Thomas E.K., Connelly R.J., Pennathur S., Dubrovsky L., Haffar O.K., and **Bukrinsky M.** (1996). Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: A possible role of intermediate filaments in the early steps of HIV-1 infection cycle. *Viral Immunol.* 9:73-87.
41. Chao C.C., Hu S., Sheng W.S., Bu D., **Bukrinsky M.**, and Peterson P.K. (1996). Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. *Glia* 16:276-284.
42. **Bukrinsky M.**, Schmidtmayerova H., Zybarth G., Dubrovsky L., Sherry B., and Enikolopov G. (1996). A critical role of nitric oxide in human immunodeficiency virus type 1-induced hyperresponsiveness of cultured monocytes. *Mol. Med.* 2:460-468.
43. Popov S., Dubrovsky L., Lee M.-A., Pennathur S., Haffar O., Al-Abed Y., Tonge P., Ulrich P., Rexach M., Blobel G., Cerami A., and **Bukrinsky M.** (1996). Critical role of reverse transcriptase in the inhibitory mechanism of CN1-H0294 on HIV-1 nuclear translocation. *Proc. Natl. Acad. Sci. U.S.A.* 93:11859-11864.
44. Schmidtmayerova H., Sherry B., and **Bukrinsky M.** (1996). Chemokines and HIV replication. *Nature* 382:767.
45. Schmidtmayerova H., Nuovo G., and **Bukrinsky M.** (1997). Cell proliferation is not required for productive HIV-1 infection of macrophages. *Virology* 232:379-384.
46. **Bukrinsky M.**, Sherry B., Schmidtmayerova H., Raabe T., and Dubrovsky L. (1997). Differential regulation by nitric oxide: Production of macrophage inflammatory protein. In "HIV and Cytokines", M. Guenounou (ed.). *Les Editions INSERM*, Paris, pp. 89-97.
47. Cohen P.S., Schmidtmayerova H., Dennis J., Dubrovsky L., Sherry B., Wang H., **Bukrinsky M.**, and Tracey K.J. (1997). The critical role of p38 MAP kinase in T cell HIV-1 replication. *Mol. Med.* 3:339-346.
48. Popov S., Rexach M., Zybarth G., Reiling N., Lee M.-A., Ratner L., Lane C.M., Moore M.S., Blobel G., and **Bukrinsky M.** (1998). Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. *EMBO J.* 17:909-917.
49. Sherry B., Zybarth G., Alfano M., Dubrovsky L., Mitchell R., Rich D., Ulrich P., Bucala R., Cerami A., and **Bukrinsky M.** (1998). Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. *Proc. Natl. Acad. Sci. U.S.A.* 95:1758-1763.

50. Raabe T., **Bukrinsky M.**, and Currie R.A. (1998). Relative contribution of transcription and translation to the induction of tumor necrosis factor- α by lipopolysaccharide. *J. Biol. Chem.* 273:974-980.
51. Popov S., Rexach M., Ratner L., Blobel G., and **Bukrinsky M.** (1998). Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. *J. Biol. Chem.* 273: 13347-13352.
52. Haffar O.K., Smithgall M.D., Popov S., Ulrich P., Bruce A.G., Nadler S.G., Cerami A., and **Bukrinsky M.** (1998). CNI-H0294, a nuclear importation inhibitor of the human immunodeficiency virus type 1 genome, abrogates virus replication in infected activated peripheral blood mononuclear cells. *Antimicrob. Agents Chemother.* 42: 1133-1138.
53. Schmidtayerova H., Alfano M., Nuovo G., and **Bukrinsky M.** (1998). Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. *J. Virol.* 72: 4633-4642.
54. Alfano M., Schmidtayerova H., and **Bukrinsky M.** (1998). Bacterial lipopolysaccharide is a potent inhibitor of HIV-1 replication in T lymphocytes and macrophages. *AIDS* 12:10-12.
55. Zybarth G., Reiling N., Schmidtayerova H., Sherry B., and **Bukrinsky M.** (1999). Activation-induced resistance of human macrophages to HIV-1 infection in vitro. *J. Immunol.* 162:400-406.
56. Alfano M., Amella C.-A., Schmidtayerova H., and **Bukrinsky M.** (1999). The B-oligomer of pertussis toxin deactivates CC-chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. *J. Exp. Med.* 190:597-605 (Cover article).
57. Franchin G., Zybarth G., Dai W.W., Dubrovsky L., Reiling N., Schmidtayerova H., **Bukrinsky M.**, and Sherry B. (2000). Lipopolysaccharide inhibits HIV-1 infection of monocyte-derived macrophages through direct and sustained downregulation of CCR5 receptors. *J. Immunol.* 164:2592-2601.
58. Haffar O.K., Popov S., Dubrovsky L., Agostini I., Tang H., Pushkarsky T., Nadler S.G., and **Bukrinsky M.** (2000). Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. *J. Mol. Biol.* 299:359-368.
59. Glushakova S., Dubrovsky L., Grivel J.-C., Haffar O.K., and **Bukrinsky M.** (2000). Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue *ex vivo*: A potential addition to current anti-HIV drug repertoire. *Antiviral Res.* 47:89-95.
60. Sherry B., Schmidtayerova H., Zybarth G., Dubrovsky L., Raabe T., and **Bukrinsky M.** (2000). Nitric oxide regulates MIP-1 α expression in primary macrophages and T lymphocytes: implications for anti-HIV-1 response. *Mol. Med.* 6:542-549.
61. Agostini I., Popov S., Li J., Dubrovsky L., and **Bukrinsky M.** (2000). Heat-shock protein 70 can replace viral protein R of HIV-1 during nuclear import of the viral pre-integration complex. *Exp. Cell Res.* 259:398-403.

62. Alfano M., Pushkarsky T., Poli G., and **Bukrinsky M.** (2000). The B-oligomer of pertussis toxin inhibits HIV-1 replication at multiple stages. *J. Virol.* 74:8767-8770.
63. Alfano M., Vallanti G., Biswas P., Bovolenta C., Vicenzi E., Rappuoli R., Lazzarin A., **Bukrinsky M.***, and Poli G*. (2001). The B-oligomeric subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells. *J. Immunol.* 166:1863-1870.
- *Equal contribution.
64. Gujuluva C., Burns A.R., Pushkarsky T., Popik W., Berger O., **Bukrinsky M.**, Graves M.C., and Fiala M. (2001). HIV-1 penetrates coronary artery endothelial cells by transcytosis. *Mol. Med.* 7:169-176.
65. Pushkarsky T., Zybarth G., Dubrovsky L., Yurchenko V., Guo H., Toole B., Sherry B., and **Bukrinsky M.** (2001). CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. *Proc. Natl. Acad. Sci. U.S.A.* 98:6360-6365.
66. Yurchenko V., O'Connor M., Dai W.W., Guo H., Toole B., Sherry B., and **Bukrinsky M.** (2001). CD147 is a signaling receptor for cyclophilin B. *Biochem. Biophys. Res. Commun.* 288:786-788.
67. Pushkarsky T., Dubrovsky L., and **Bukrinsky M.** (2001). Lipopolysaccharide stimulates HIV-1 entry and degradation in human macrophages. *Endotox. Res.* 7:271-276.
68. Agostini I., Popov S., Hao T., Li J-H., Dubrovsky L., Chaika O., Chaika N., Lewis R., and **Bukrinsky M.** (2002). Phosphorylation of Vpr regulates HIV-1 nuclear import and macrophage infection. *AIDS Res. Human Retroviruses* 18:283-288.
69. Liu N.Q., Lossinsky A.S., Popik W., Li X., Gujuluva C., Kriederman B., Pushkarsky T., **Bukrinsky M.**, Witte M., Weinand M., and Fiala M. (2002). Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent upon lipid rafts and mitogen-activated protein kinase signaling pathway. *J. Virol.* 76:6689-6700.
70. Yurchenko V., Zybarth G., O'Connor M., Dai W.W., Franchin G., Hao T., Guo H., Hung H.-C., Toole B., Galloway P., Sherry B., and **Bukrinsky M.** (2002). Active-site residues of cyclophilin A are crucial for its signaling activity via CD147. *J. Biol. Chem.* 277:22959-22965.
71. Twu C., Liu N.Q., Popik W., **Bukrinsky M.**, Sayre J., Roberts J., Rania S., Bramhandam V., Roos K.P., MacLellan W.R., and Fiala M. (2002). Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. *Proc. Natl. Acad. Sci. U.S.A.* 99:14386-14391.
72. Iordanskiy S., Iordanskaya T., Quivy V., Van Lint C., and **Bukrinsky M.** (2002). B-Oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NF- κ B p65 subunit activity. *Virology* 302:195-206.
73. Di Marzio P., Sherry B., Thomas E.K., Franchin G., Schmidtmayerova H., and **Bukrinsky M.** (2003). β -Chemokine production in CD40L-stimulated monocyte-derived macrophages requires activation of MAPK signaling pathways. *Cytokine* 23:53-63

74. Iordanskiy S., Zhao Y., DiMarzio P., Agostini I., Dubrovsky L., and **Bukrinsky M.** (2004). Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. *Blood* 104:1867-1872.
75. **Bukrinsky M.** and Zhao Y. (2004). Heat-shock proteins reverse the G₂ arrest caused by HIV-1 viral protein R. *DNA Cell Biol.* 23:223-225.
76. Iordanskiy S., Zhao Y., Dubrovsky S., Iordanskaya T., Chen M., Liang D., and **Bukrinsky M.** (2004). Heat-shock protein 70 protects cells from cell cycle arrest and apoptosis induced by HIV-1 viral protein R. *J. Virol.* 78:9697-9704.
77. Benko Z., Liang D., Agbottah E., Hou J., Chiu K., Yu M., Innis S., Reed P., Kabat W., Elder R.T., Di Marzio P., Taricani L., Ratner L., Young P.G., **Bukrinsky M.**, and Zhao R.Y. (2004). Antagonistic interactions between small heat shock proteins and HIV-1 viral protein R. *J. Virol.* 78:11016-11029.
78. Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B and **Bukrinsky M.** (2005). Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. *J. Biol Chem.* 280:17013-17019.
79. Arora K, Gwinn WM, Bower MA, Watson A, Okwumabua I, Macdonald HR, **Bukrinsky M.**, and Constant SL. (2005). Extracellular cyclophilins contribute to the regulation of inflammatory responses. *J. Immunol.* 175:517-522.
80. Pushkarsky T, Yurchenko V, Vanpouille C, Brichacek B, Vaisman I, Hatakeyama S, Nakayama KI, Sherry B, and **Bukrinsky M.** (2005). Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. *J. Biol. Chem.* 280:27866-27871.
81. Haffar O, Dubrovsky L, Lowe R, Berro R, Kashanchi F, Godden J, Vanpouille C, Bajorath J, and **Bukrinsky M.** (2005). Oxadiazols: a new class of rationally designed anti-HIV compounds targeting nuclear localization signal of the viral matrix protein. *J. Virol.* 79:13028-13036.
82. Iordanskiy S, Berro R, Altieri M, Kashanchi F, and **Bukrinsky M.** (2006). Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin. *Retrovirology* 3:4.
83. Brichacek B, Vanpouille C, Trachtenberg AJ, Pushkarsky T, Dubrovsky L, Martin G, Simon G, and **Bukrinsky M.** (2006). Long-term changes of serum chemokine levels in vaccinated military personnel. *BMC Immunol.* 7:21.
84. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, **Bukrinsky M.***, and Sviridov D (2006). Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. *PLoS Biol.* 4:e365.
- *Corresponding author
85. Gwinn WM, Damsker JM, Falahati R, Okwumabua I, Kelly-Welch A, Keegan AD, Vanpouille C, Lee JJ, Dent LA, Leitenberg D, **Bukrinsky M.**, and Constant SL (2006). Novel

approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. *J. Immunol.* 177:4870-4879.

86. **Bukrinsky M.** and Sviridov D (2007). HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis (commentary). *PLoS Med.* 4:e43.
87. Benko Z, Liang D, Agbottah E, Hou J, Taricani L, Young PG, **Bukrinsky M.** and Zhao RY. (2007). Antagonistic interaction of HIV-1 Vpr with Hsf-mediated cellular heat shock response and Hsp16 in fission yeast (*Schizosaccharomyces pombe*). *Retrovirology* 4:16.
88. Damsker JM, **Bukrinsky M.**, Constant SL. (2007). Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. *J. Leukoc. Biol.* 82:613-618.
89. Mukhamedova N, Fu Y, **Bukrinsky M.**, Remaley A, Sviridov D. (2007). The role of different regions of ABCA1 in cholesterol efflux. *Biochemistry* 46:9388-9398.
90. Liang D, Benko Z, Agbottah E, **Bukrinsky M.***, Zhao RY. (2007). Anti-Vpr activities of heat-shock protein 27. *Mol. Med.* 13:229-239.

*Corresponding author

91. Pushkarsky T, Yurchenko V, Laborico A, and **Bukrinsky M.** (2007). CD147 stimulates HIV-1 infection in a signal-independent fashion. *Biochem. Biophys. Res. Com.* 363:495-499.
92. Yurchenko V, Xue Z, Sherry B and **Bukrinsky M.** (2008). Functional analysis of *Leishmania major* cyclophilin. *Int. J. Parasitol.* 38:633-639.
93. Wu W, Kehn-Hall K, Pedati C, Zweier L, Castro I, Klase Z, Dowd CS, Dubrovsky L, **Bukrinsky M.**, and Kashanchi F. (2008). Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. *Viol J.* 5:41.
94. Rose H, Hoy J, Woolley I, Tchoua U, **Bukrinsky M.**, Dart A, and Sviridov D. (2008). HIV infection and high density lipoprotein metabolism. *Atherosclerosis* 199:79-86.
95. Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, Krozowski Z, **Bukrinsky M.**, and Sviridov D. (2008). Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. *J. Lipid Res.* 49:2312-2322.
96. Damsker JM, Okwumabua I, Pushkarsky T, Arora K, **Bukrinsky M.**, and Constant SL. (2009). Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. *Immunology* 126:55-62.
97. Mukhamedova N, Rose H, Cui HL, Grant A, Tchoua U, Dart A, **Bukrinsky M.**, Sviridov D. (2009). Antiretroviral compounds and cholesterol efflux from macrophages. *Atherosclerosis* 206:439-443.
98. Kadiu I, Wang T, Schlautman JD, Dubrovsky L, Ciborowski P, **Bukrinsky M.**, Gendelman HE. (2009). HIV-1 transforms the monocyte plasma membrane proteome. *Cell Immunol.* 258:44-58.
99. Iordanskiy SN, **Bukrinsky M.** (2009). Analysis of viral and cellular proteins in HIV-1 reverse transcription complexes by co-immunoprecipitation. *Methods Mol Biol.* 485:121-34.

100. Li G, **Bukrinsky M.**, Zhao RY. (2009). HIV-1 viral protein R (Vpr) and its interactions with host cell. *Curr HIV Res.* 7:178-183.
101. Schlegel J, Redzic JS, Porter CC, Yurchenko V, **Bukrinsky M.**, Labeikovskiy W, Armstrong GS, Zhang F, Isern NG, DeGregori J, Hodges R, Eisenmesser EZ. (2009). Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. *J Mol Biol.* 391:518-535.
102. Malesević M, Kühling J, Erdmann F, Balsley MA, **Bukrinsky M.**, Constant SL, Fischer G. (2010). A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. *Angew Chem Int Ed Engl.* 49:213-215.
103. Morrow MP, Grant A, Mujawar Z, Dubrovsky L, Pushkarsky T, Kiselyeva Y, Jennelle L, Mukhamedova N, Remaley AT, Kashanchi F, Sviridov D, **Bukrinsky M.** (2010). Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. *Mol Pharmacol.* 78:215-225.
104. Weinstein RS, Weinstein MM, Alibek K, **Bukrinsky M.**, Brichacek B. (2010). Significantly reduced CCR5-tropic HIV-1 replication in vitro in cells from subjects previously immunized with Vaccinia Virus. *BMC Immunol.* 11:23.
105. Li G, Elder RT, Dubrovsky L, Liang D, Pushkarsky T, Chiu K, Fan T, Sire J, **Bukrinsky M.**, Zhao RY. (2010). HIV-1 replication through hHR23A-mediated interaction of Vpr with 26S proteasome. *PLoS One* 5:e11371.
106. Asztalos BF, Mujawar Z, Morrow MP, Grant A, Pushkarsky T, Wanke C, Shannon R, Geyer M, Kirchhoff F, Sviridov D, Fitzgerald ML, **Bukrinsky M.**, Mansfield KG. (2010). Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. *J Infect Dis.* 202:614-623.
107. Mujawar Z, Tamehiro N, Grant A, Sviridov D, **Bukrinsky M.**, Fitzgerald ML. (2010). Mutation of the ATP Cassette Binding Transporter A1 (ABCA1) C-Terminus Disrupts HIV-1 Nef Binding but Does Not Block the Nef Enhancement of ABCA1 Protein Degradation. *Biochemistry* 49:8338-8349.
108. Balsley MA, Malesevic M, Stemmy EJ, Gigley J, Jurjus RA, Herzog D, **Bukrinsky M.**, Fischer G, Constant SL. (2010). A cell-impermeable cyclosporine derivative reduces pathology in a mouse model of allergic lung inflammation. *J Immunol.* 185:7663-7670.
109. Stemmy EJ, Balsley MA, Jurjus RA, Damsker JM, **Bukrinsky M.**, Constant SL. (2011). Blocking Cyclophilins in Chronic Phase of Asthma Reduces Leukocyte Persistence and Disease Reactivation. *Am J Respir Cell Mol Biol.* 45:991-998.
110. Trachtenberg A, Pushkarsky T, Heine S, Constant S, Brichacek B, **Bukrinsky M.** (2011). The level of CD147 expression correlates with cyclophilin-induced signaling and chemotaxis. *BMC Res Notes* 4:396.
111. Heine SJ, Olive D, Gao JL, Murphy PM, **Bukrinsky M.**, Constant SL. (2011). Cyclophilin A cooperates with MIP-2 to augment neutrophil migration. *J Inflamm Res.* 4:93-104.

112. Dubrovsky L, Duayne RV, Senina S, Guendel I, Pushkarsky T, Sviridov D, Kashanchi F, **Bukrinsky M.** (2012). Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection. *Biochem Biophys Res Commun.* 419: 95-98.
113. Cui HL, Grant A, Mukhamedova N, Pushkarsky T, Jennelle L, Dubrovsky L, Gaus K, Fitzgerald ML, Sviridov D, **Bukrinsky M.** (2012). HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. *J Lipid Res.* 53: 696-708.
114. Santos S, Obukhov Y, Nekhai S, **Bukrinsky M.**, Iordanskiy S. (2012). Virus-producing cells determine the host protein profiles of HIV-1 virion cores. *Retrovirology* 9:65.
115. Rose H, Low H, Dewar E, **Bukrinsky M.**, Hoy J, Dart A, Sviridov D. (2013). The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. *Atherosclerosis* 229: 206-211.
116. Cui HL, Guo B, Scicluna B, Coleman BM, Lawson VA, Ellett L, Meikle PJ, **Bukrinsky M.**, Mukhamedova N, Sviridov D, Hill AF. (2014). Prion infection impairs cholesterol metabolism in neuronal cells. *J Biol Chem.* 289: 789-802.
117. Jacob D, Hunegnaw R, Sabyrzanova TA, Pushkarsky T, Chekhov VO, Adzhubei AA, Kalebina TS, **Bukrinsky M.** (2014). The ABCA1 domain responsible for interaction with HIV-1 Nef is conformational and not linear. *Biochem Biophys Res Commun.* 444: 19-23.
118. Cui HL, Ditiatkovski M, Kesani R, Bobryshev YV, Liu Y, Geyer M, Mukhamedova N, **Bukrinsky M.**, Sviridov D. (2014). HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. *FASEB J.* 28: 2828-2839.
119. Jennelle L, Hunegnaw R, Dubrovsky L, Pushkarsky T, Fitzgerald ML, Sviridov D, Popratiloff A, Brichacek B, **Bukrinsky M.** (2014). HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin. *J Biol Chem.* 289: 28870-28884.
120. Brichacek B, Darwish C, Popratiloff A, Dubrovsky L, **Bukrinsky M.** (2014). HIV-1 infection of macrophages induces retention of cholesterol transporter ABCA1 in the endoplasmic reticulum. *AIDS Res Hum Retroviruses* 30: 947-948.
121. Ditiatkovski M, Neelisetti VN, Cui HL, Malesevic M, Fischer G, **Bukrinsky M.**, Sviridov D. (2015). Inhibition of extracellular cyclophilins with cyclosporine analog and development of atherosclerosis in apolipoprotein E-deficient mice. *J Pharmacol Exp Ther.* 353: 490-495.
122. Ramezani A, Dubrovsky L, Pushkarsky T, Sviridov D, Karandish S, Raj DS, Fitzgerald ML, **Bukrinsky M.** (2015). Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection. *J Pharmacol Exp Ther.* 354: 376-383.
123. Iordanskaia T, Malesevic M, Fischer G, Pushkarsky T, **Bukrinsky M.***, Nadler E. (2015). Targeting extracellular cyclophilins ameliorates disease progression in experimental biliary atresia. *Mol Med.* In press. doi: 10.2119/molmed.2015.00076.

*Corresponding author

124. Siegel MO, Borkowska AG, Dubrovsky L, Roth M, Welti R, Roberts AD, Parenti DM, Simon GL, Sviridov D, Simmens S, **Bukrinsky M.***, Fitzgerald ML. (2015). HIV infection induces structural and functional changes in high density lipoproteins. *Atherosclerosis* 243: 19-29.

*Corresponding author

125. Meikle P, Low H, Churchill MJ, **Bukrinsky M**, Sviridov D. (2015). Lipidomic dataset of plasma from patients infected with wild type and Nef-deficient HIV-1 strain. *Data Brief*. 6: 168-175.

126. Low H, Cheng L, Di Yacovo MS, Churchill MJ, Meikle P, **Bukrinsky M**, Hill AF, Sviridov D. (2016). Lipid metabolism in patients infected with Nef-deficient HIV-1 strain. *Atherosclerosis* 244: 22-28.

127. Siegel J, Darwish C, Popratiloff A, **Bukrinsky M***, Brichacek B. (2016). Live Cell Imaging of ABCA1 Downregulation by HIV-1 Nef in an Experimental Model of HeLa ABCA1-GFP. *AIDS Res Hum Retroviruses*. 32: 872-873.

*Corresponding author

128. Low H, Mukhamedova N, Cui HL, McSharry BP, Avdic S, Hoang A, Ditiatkovski M, Liu Y, Fu Y, Meikle PJ, Blomberg M, Polyzos KA, Miller WE, Religa P, **Bukrinsky M**, Soderberg-Naucler C, Slobedman B, Sviridov D. (2016). Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells. *Cell Rep*. 16: 186-200.

129. Santos S, Obukhov Y, Nekhai S, Pushkarsky T, Brichacek B, **Bukrinsky M***, Iordanskiy S. (2016). Cellular minichromosome maintenance complex component 5 (MCM5) is incorporated into HIV-1 virions and modulates viral replication in the newly infected cells. *Virology* 497: 11-22.

*Corresponding author

130. Hunegnaw R, Vassilyeva M, Dubrovsky L, Pushkarsky T, Sviridov D, Anashkina AA, Üren A, Brichacek B, Vassilyev DG, Adzhubei AA, **Bukrinsky M**. (2016). Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. *Arterioscler Thromb Vasc Biol*. 36: 1758-1771.

131. Mukhamedova N, Hoang A, Cui HL, Carmichael I, Fu Y, **Bukrinsky M**, Sviridov D. (2016). Small GTPase ARF6 Regulates Endocytic Pathway Leading to Degradation of ATP-Binding Cassette Transporter A1. *Arterioscler Thromb Vasc Biol*. 36: 2292-2303.

132. Suttiprapa S, Rinaldi G, Tsai IJ, Mann VH, Dubrovsky L, Yan HB, Holroyd N, Huckvale T, Durrant C, Protasio AV, Pushkarsky T, Iordanskiy S, Berriman M, **Bukrinsky MI***, Brindley PJ. (2016). HIV-1 Integrates Widely throughout the Genome of the Human Blood Fluke *Schistosoma mansoni*. *PLoS Pathog*. 12: e1005931.

*Corresponding author

133. Volotskova O, Dubrovsky L, Keidar M, **Bukrinsky M.** (2016). Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells. *PLoS One* 11: e0165322.

134. Pushkarsky T, Shilov E, Kruglova N, Naumann R, Brichacek B, Jennelle L, Sviridov D, Kruglov A, Nedospasov SA, **Bukrinsky M.** (2017). Short Communication: Accumulation of Neutral Lipids in Liver and Aorta of Nef-Transgenic Mice. *AIDS Res Hum Retroviruses* 33: 57-60.

135. Kuniholm MH, Liang H, Anastos K, Gustafson D, Kassaye S, Nowicki M, Sha BE, Pawlowski EJ, Gange SJ, Aouizerat BE, Pushkarsky T, **Bukrinsky MI***, Prasad VR. (2017). Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfecting women. *AIDS* 31: 2483-2492.

*Senior author

136. Kirichenko TV, Myasoedova VA, Shimonova TE, Melnichenko AA, Sviridov D, Sobenin IA, Mazus AI, Orekhov AN, **Bukrinsky MI.** (2018). Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. *Biosci Rep.* 38: BSR20180597.

137. Adzhubei AA, Anashkina AA, Tkachev YV, Kravatsky YV, Pushkarsky T, Kulkarni A, Makarov AA, **Bukrinsky MI.** (2018). Modelling interaction between HIV-1 Nef and calnexin. *AIDS* 32:2103-2111.

138. Orekhov AN, Pushkarsky T, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, Makeev VJ, Foxx K, Jin X, Kruth HS, Sobenin IA, Sukhorukov VN, Zakiev ER, Kontush A, Le Goff W, **Bukrinsky M.** (2018). HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages. *Exp Mol Pathol.* 105:202-207.

139. Orekhov AN, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, Sobenin IA, Kel A, Stelmashenko D, Makeev VJ, Foxx K, Jin X, Kruth HS, **Bukrinsky M.** (2018). Modified LDL particles activate inflammatory pathways in monocyte-derived macrophages: transcriptome analysis. *Curr Pharm Des.* 24:3143-3151.

140. Low H, Hoang A, Pushkarsky T, Dubrovsky L, Dewar E, Di Yacovo MS, Mukhamedova N, Cheng L, Downs C, Simon G, Saumoy M, Hill AF, Fitzgerald ML, Nestel P, Dart A, Hoy J, **Bukrinsky M***, Sviridov D. (2019). HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. *PLoS One* 14:e0215620.

*Senior author

141. Dhanda AS, Lulic KT, Yu C, Chiu RH, **Bukrinsky M,** Guttman JA. (2019). *Listeria monocytogenes* hijacks CD147 to ensure proper membrane protrusion formation and efficient bacterial dissemination. *Cell Mol Life Sci.* 76:4165-4178.

142. Mukhamedova N, Hoang A, Dragoljevic D, Dubrovsky L, Pushkarsky T, Low H, Ditiatkovski M, Fu Y, Ohkawa R, Meikle PJ, Horvath A, Brichacek B, Miller YI, Murphy A, **Bukrinsky M***, Sviridov D. (2019). Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells. *PLoS Pathog.* 15:e1007907.

*Senior author

143. Zicari S, Sharma AL, Sahu G, Dubrovsky L, Sun L, Yue H, Jada T, Ochem A, Simon G, **Bukrinsky M**, Tyagi M. (2020). DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR. *Oncotarget* 11:699–726.
144. Dubrovsky L, Ward A, Choi SH, Pushkarsky T, Brichacek B, Vanpouille C, Adzubei AA, Mukhamedova N, Sviridov D, Margolis L, Jones RB, Miller YI, **Bukrinsky M**. (2020). Inhibition of HIV replication by apolipoprotein A-I binding protein targeting the lipid rafts. *mBio* 11:e02956-19.
145. Sharma AL, Hokello J, Sonti S, Zicari S, Sun L, Alqatawni A, **Bukrinsky M**, Simon G, Chauhan A, Daniel R, Tyagi M. (2020). CBF-1 Promotes the Establishment and Maintenance of HIV Latency by Recruiting Polycomb Repressive Complexes, PRC1 and PRC2, at HIV LTR. *Viruses* 12:1040.
146. Resop RS, Fromentin R, Newman D, Rigsby H, Dubrovsky L, **Bukrinsky M**, Chomont N, Bosque A. (2020). Fingolimod inhibits multiple stages of the HIV-1 life cycle. *PLoS Pathog.* 16:e1008679.
147. Low H, Mukhamedova N, Capettini LDSA, Xia Y, Carmichael I, Cody SH, Huynh K, Ditiatkovski M, Ohkawa R, **Bukrinsky M**, Meikle PJ, Choi SH, Field S, Miller YI, Sviridov D. (2020). Cholesterol Efflux-Independent Modification of Lipid Rafts by AIBP (Apolipoprotein A-I Binding Protein). *Arterioscler Thromb Vasc Biol.* 40:2346-2359.
149. Ditiatkovski M, Mukhamedova N, Dragoljevic D, Hoang A, Low H, Pushkarsky T, Fu Y, Carmichael I, Hill AF, Murphy AJ, **Bukrinsky M**, Sviridov D. (2020). Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction. *J Biol Chem.* 295:13377-13392.
150. Park MH, Suhaim JL, Elmastour F, Singha SK, Imafuku T, Venkatnarayan R, Christ A, Grebe A, Oppelt SA, Sviridov D, **Bukrinsky M**, Latz E, Potma EO, Fitzgerald ML. (2021). Non-linear optical imaging of atherosclerotic plaques in the context of SIV and HIV infection prominently detects crystalline cholesterol esters. *PLoS One* 16:e0251599.
151. Adzubei AA, Kulkarni A, Tolstova AP, Anashkina AA, Sviridov D, Makarov AA, **Bukrinsky MI**. (2021). Direct interaction between ABCA1 and HIV-1 Nef: Molecular modeling and virtual screening for inhibitors. *Comput Struct Biotechnol J.* 19:3876-3884.
152. Pushkarsky T, Ward A, Ivanov A, Lin X, Sviridov D, Nekhai S, **Bukrinsky MI**. (2022). Abundance of Nef and p-Tau217 in brains of individuals diagnosed with HIV-associated neurocognitive disorders correlate with disease severance. *Mol Neurobiol.* 59:1088-1097.
153. Dubrovsky L, Brichacek B, Prashant NM, Pushkarsky T, Mukhamedova N, Fleetwood AJ, Xu Y, Dragoljevic D, Fitzgerald M, Horvath A, Murphy AJ, Sviridov D, **Bukrinsky MI**. (2022). Extracellular vesicles carrying HIV-1 Nef induce long-term hyperreactivity of myeloid cells. *Cell Rep.* 41:111674.

CHAPTERS & REVIEWS (PEER-REVIEWED):

1. **Bukrinsky M.I.** (1987). Genome structure and gene expression of the human immunodeficiency virus (a review of the foreign literature). *Vopr. Virusol.* (Russian) 6:649-656.
2. Bukrinskaya A.G., **Bukrinsky M.I.** (1988). Human immunodeficiency virus: From genome structure to vaccine. *Trends in Modern Biology* (Russian) 105:163-176.
3. Stevenson M., **Bukrinsky M.I.**, Haggerty S. (1992). HIV-1 replication and potential targets for intervention. *AIDS Res. Human Retroviruses* 8:107-117.
4. Gendelman H., Lipton S.A., Tardieu M., **Bukrinsky M.I.**, Nottet H.S.L.M. (1994). The neuropathogenesis of HIV-1 infection. *J. Leuk. Biol.* 56:7311 -7315.
5. **Bukrinsky M.** (1997). Inhibitors of the nuclear translocation of the HIV-1 preintegration complex. *Drugs of the Future*, 22:875-883.
6. **Bukrinsky M.I.** and Haffar O.K. (1997). HIV-1 nuclear import: in search of a leader. *Front. Biosci.* 2:578-587.
7. **Bukrinsky M.I.** and Haffar O.K. (1998). HIV-1 nuclear import: matrix protein is back on center stage, this time together with Vpr. *Mol. Med.* 4:138-143 (Cover article).
8. **Bukrinsky M.** and Adzhubei A. (1999). Viral protein R of HIV-1. *Rev. Med. Virol.* 9:39-49.
9. Fiala M., Gujuluva C., Berger O., **Bukrinsky M.**, Kim K.S., Graves M.C. (2001). Chemokine receptors on brain endothelia--keys to HIV-1 neuroinvasion? *Adv. Exp. Med. Biol.* 493:35-40.
10. **Bukrinsky M.** (2001). HIV Life Cycle and Inherited Coreceptors. In: Encyclopedia of Life Sciences, Nature Publishing Group. <http://www.els.net>.
11. **Bukrinsky M.** (2002). Cyclophilins: Unexpected messengers in intercellular communications. *Trends Immunol.* 23:323-325.
12. Brichacek B and **Bukrinsky M.** (2002). Highly active antiretroviral therapy and beta-chemokines. *Clin. Exp. Immunol.* 130:169-171.
13. **Bukrinsky M.** (2004). A hard way to the nucleus. *Mol. Med.* 10:1-6.
14. **Bukrinsky M.** (2005). Nuclear Import and Export of Mammalian Viruses. In: Nuclear Import and export in Plants and Animals, eds. T. Tzfira and V. Citovsky, Landes Bioscience, Georgetown, TX. <http://www.eurekah.com>.
15. Ghorpade A., Brichacek B. and **Bukrinsky M.** (2005). The molecular biology of HIV-1. In: 'The Neurology of AIDS Second Edition', Eds. Gendelman H., Grant I., Everall I.P., Lipton S., and Swindells S. Oxford University Press.
16. Haffar O. and **Bukrinsky M.** (2005). Nuclear translocation as a novel target for anti-HIV drugs. *Expert Rev Anti Infect Ther.* 3:41-50.

17. Li L, Li HS, Pauza CD, **Bukrinsky M.**, and Zhao RY. (2005). Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. *Cell Res.* 15:923-934.
18. Zhao RY, **Bukrinsky M.**, and Elder RT. (2005). HIV-1 viral protein R (Vpr) and host cellular responses. *Indian J. Med. Res.* 121:270-286.
19. Yurchenko V., Constant S., and **Bukrinsky M.** (2006). Dealing with the Family: CD147 interactions with cyclophilins. *Immunology* 117:301-309.
20. **Bukrinsky M.** and Sviridov D. (2006). Human immunodeficiency virus infection and macrophage cholesterol metabolism. *J. Leukoc. Biol.* 80:1044-1051.
21. **Bukrinsky M.** (2006). SNFing HIV transcription. *Retrovirology* 3:49.
22. Iordanskiy S. and **Bukrinsky M.** (2007). Reverse transcription complex: the key player of the early phase of HIV replication. *Future Virology* 2:49-64.
23. Sviridov, D., **Bukrinsky M.**, Kingwell, B.A., Hoy, J. (2007). HDL in Health and Disease: Effects of Exercise and HIV Infection on HDL Metabolism. In: "High-Density Lipoproteins. From Basic Biology to Clinical Aspects" (Fielding, C., ed), Willey-VCH, Hamburg, pp. 355-374.
24. Zhao R.Y., Elder R.T., **Bukrinsky M.** (2007). Interactions of HIV-1 Viral Protein R with Host Cell Proteins. *Adv Pharmacol.* 55C:233-260.
25. Bukrinskaya A.G. and **Bukrinsky M.** (2007). Intracellular transport of human immunodeficiency virus. *Biochemistry* (Moscow), Suppl. Series A: Membrane and Cell Biology, 1:271-277.
26. Benko Z., Elder R.T., **Bukrinsky M.**, Zhao R.Y. (2008). Heat shock proteins as possible anti HIV agents. In: "Heat Shock Proteins: New Research" (eds. Morel E. and Vincent C.), Nova Science Publishers, Hauppauge, NY.
27. Iordanskiy S.N., **Bukrinsky M.** (2009). Analysis of viral and cellular proteins in HIV-1 reverse transcription complexes by co-immunoprecipitation. In "HIV Protocols", Second edition (eds. Prasad V.R. and Kalpana G.V.), Humana Press, New York, NY.
28. Yurchenko V, Constant S, Eisenmesser E, **Bukrinsky M.** (2010). Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. *Clin Exp Immunol.* 160:305-317.
29. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, **Bukrinsky M.** (2010). The macrophage: the intersection between HIV infection and atherosclerosis. *J Leukoc Biol.* 87:589-598.
30. Levin A, Loyter A, **Bukrinsky M.** (2010). Strategies to inhibit viral protein nuclear import: HIV-1 as a target. *Biochim Biophys Acta* 1813:1646-1653.
31. Zhao RY, Li G, **Bukrinsky M.** (2011). Vpr-Host Interactions During HIV-1 Viral Life Cycle. *J. Neuroimmune Pharmacol.* 6:216-229.
32. Tyagi M, **Bukrinsky M.** (2012). HIV latency: the major hurdle in HIV eradication. *Mol Med.* 18:1096-108.

33. **Bukrinsky M.**, Orekhov A, Ditiatkovski M, Sviridov D. (2013). Cyclophilins in Atherosclerosis: A new Therapeutic Target? *Curr Pharm Des.* 19: 5904-5908.
34. Iordanskiy S, Santos S, **Bukrinsky M.** (2013). Nature, nurture and HIV: The effect of producer cell on viral physiology. *Virology* 443: 208-213.
35. Zhao RY, **Bukrinsky M.** (2014). HIV-1 accessory proteins: VpR. *Methods Mol Biol.* 1087: 125-134.
36. Sviridov D, **Bukrinsky M.** (2014). Interaction of pathogens with host cholesterol metabolism. *Curr Opin Lipidol.* 25: 333-338.
37. Prasad VR, **Bukrinsky M.** (2014). New clues to understanding HIV nonprogressors: low cholesterol blocks HIV trans infection. *MBio* 5: e01396-14.
38. **Bukrinsky M.** (2015). Extracellular cyclophilins in health and disease. *Biochim Biophys Acta* 1850: 2087-2095.
39. Tyagi M, Weber J, **Bukrinsky M**, Simon GL. (2016). The effects of cocaine on HIV transcription. *J Neurovirol.* 22: 261-274.
40. Mukhamedova N, Brichacek B, Darwish C, Popratiloff A, Sviridov D, **Bukrinsky M.** (2016). Analysis of ABCA1 and cholesterol efflux in HIV-infected cells. *Methods Mol Biol.* 1354:281-92.
41. Tyagi M, **Bukrinsky M**, Simon GL. (2016). Mechanisms of HIV transcriptional regulation by drugs of abuse. *Curr HIV Res.* 14:442-454.
42. **Bukrinsky M.** (2017). Yeast help identify cytopathic factors of Zika virus. *Cell Biosci.* 7: 12.
43. Nikiforov NG, Elizova NV, **Bukrinsky M**, Dubrovsky L, Makeev VJ, Wakabayashi Y, Liu P, Foxx KK, Kruth HS, Jin X, Zakiev ER, Orekhov AN. (2017). Use of primary macrophages for searching novel immunocorrectors. *Curr Pharm Des.* 23:915-920.
44. **Bukrinsky MI**, Mukhamedova N, Sviridov D. (2020). Lipid rafts and pathogens: the art of deception and exploitation. *J Lipid Res.* 61:601-610.
45. Sviridov D, Mukhamedova N, Makarov AA, Adzhubei A, **Bukrinsky M.** (2020). Co-morbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality. *AIDS* 34:1-13.
46. Golubovskaya V, **Bukrinsky MI**, Grizzi F. (2020). Editorial On "Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy". *Vaccines* 8:E421.
47. Ballout RA, Sviridov D, **Bukrinsky MI**, Remaley AT. (2020). The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. *FASEB J.* 34:7253-7264.
48. Sviridov D, Miller YI, Ballout RA, Remaley AT, **Bukrinsky M.** (2020). Targeting Lipid Rafts-A Potential Therapy for COVID-19. *Front Immunol.* 11:574508.

49. Bezsonov E, Sukhorukov V, **Bukrinsky M**, Orekhov A. (2022). Editorial: Lipids and Inflammation in Health and Disease. *Front Cardiovasc Med.* 9:864429.

50. Sviridov D, Miller YI, **Bukrinsky MI**. (2022). Trained Immunity and HIV Infection. *Front Immunol.* 13:903884.

INVITED PRESENTATIONS:

- July 1991 Plenary session presentation at the 7th International Congress on AIDS, Florence, Italy. "Factors governing HIV-1 persistence in vivo."
- Dec. 1992 3rd International Symposium on Catalytic RNAs, San Diego, CA. "Retroviral infection of non-dividing cells: molecular mechanisms of HIV-1 nuclear targeting."
- June 1993 IXth International Conference on AIDS, Berlin, Germany. "Retroviral infection of non-dividing cells: molecular mechanisms of HIV-1 nuclear targeting."
- August 1994 Xth International Conference on AIDS, Yokohama, Japan. "HIV infection alters response of macrophages to activating stimuli: implications for AIDS pathogenesis."
- Sept. 1995 Fourth International Meeting 'Biology of Nitric Oxide', Amelia Island, FL. "Nitric oxide primes hyperactivation of HIV-1-infected human monocytes."
- August 1996 Xth International Congress of Virology, Jerusalem, Israel. "Differential regulation of β -chemokine expression by HIV-1 infection in macrophages and lymphocytes," "Nuclear translocation of HIV-1 pre-integration complex as a target for therapeutic intervention."
- Feb. 1997 Medical University of Munich, Munich, Germany. "Differential regulation of β -chemokines in HIV-1 infection."
- June 1997 2nd Joint Conference of NIAID's Strategic Program for Innovative Research on AIDS Treatment and NCDDG-HIV, Vienna, VA. "Role of Vpr in HIV-1 Nuclear Import."
- Sept. 1997 Institute of Human Virology 1997 Annual Meeting, Baltimore, MD. "Vpr is the Regulator of HIV-1 Nuclear Import."
- May 1999 Gordon Conference 'Viruses and Cells', Barga, Italy. "HIV-1 Nuclear Import."
- July 2004 XVth International Conference on AIDS, Bangkok, Thailand. "Hsp70 is an innate immunity factor targeting HIV-1 Vpr."
- Sept. 2005 Institute of Human Virology 2005 Annual Meeting, Baltimore, MD. "HIV impairs reverse cholesterol transport: implications for atherosclerosis and HIV life cycle."

- Feb 2009 12th CROI, Montreal, Canada. “Nef-mediated suppression of ABCA1 cholesterol efflux activity contributes to primary dyslipidemia in SIV-infected macaques.”
- August 2010 AAS 2010, Cairns, Australia. “Mechanisms of HIV-related atherosclerosis.”
- April 2012 ISA 2012 Satellite Symposium on *HDL*, Cairns, Australia. “HIV and atherosclerosis: unexpected connection.”
- Sept. 2013 Institute of Human Virology 2013 Annual Meeting, Moscow, Russia. “HIV-1 Nef regulates activity of endoplasmic reticulum chaperone calnexin.”
- Sept. 2013 International symposium on cyclophilins and foldases, Halle, Germany. “Treating inflammatory diseases with extracellular cyclosporine.”
- March 2019 Conference ‘Exosomes in Human Infectious Diseases’, Nassau, Bahamas. “Extracellular vesicles carrying HIV Nef are the key players in pathogenesis of HIV-associated co-morbidities.”
- March 2021 1st meeting of American Society of Intercellular Communications (ASIC), Bethesda, MD. “Nef-carrying EVs promote formation of inflammatory monocytes/macrophages”.
- Sept. 2021 Immunology World Forum (IWF), Copenhagen, Denmark (virtual). “Extracellular vehicles carrying HIV-1 Nef induce trained immunity in myeloid cells”.